Biosceptre Company
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue.
Industry:
Deep diagnostics
Headquarters:
Babraham, Cambridgeshire, United Kingdom
Founded Date:
2000-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Total Funding:
$16,136,146.00
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series A
Register and Claim Ownership